15,000 physicians and medical scientists recently published the Rome Covid Declaration, to alert citizens to the deadly consequences of disrupting life-saving treatment and suppressing open scientific discussion.

Consensus is clear among MDs and medical PhDs: following 20 months of exhaustive research, millions of patients treated, hundreds of clinical trials performed and scientific data shared worldwide, they conclude that healthy children and COVID recovered should be excluded from vaccine mandates and social restrictions.

Physicians also recommend legislative and administrative action, to prevent disruption of physicians’ treatments, or putting healthy children or the COVID-recovered at further risk.

15,000 physicians and medical scientists recently published the Rome Covid Declaration, to alert citizens to the deadly consequences of disrupting life-saving treatment and suppressing open scientific discussion.

More recently, medical scientists and physicians were compelled to add two specific policy points (children and natural immunity) to their Declaration, after authorities proposed aggressive decisions to force healthy children to be vaccinated, without demonstrating any net benefit against the risk, and to impose increasingly draconian measures against already immune citizens. SUPPORTING EVIDENCE
Vaccinating Children

Deaths by Age U.S. : 0-18, Centers for Disease Control (CDC) https://data.cdc.gov/NCHS/Deaths-by-Sex-Ages-0-18-years/xa4b-4pzv

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections, Petra Zimmermann, Nigel Curtis https://adc.bmj.com/content/106/5/429

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis, Tracy Beth Høeg, Allison Krug, Josh Stevenson, John Mandrola https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units, Lara S. Shekerdemian, MD, MHA; Nabihah R. Mahmood, MD; Katie K. Wolfe, MD; et al. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2766037

State-Level Data on COVID-19 child mortality, American Academy of Pediatrics https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/

Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data, C Smith, D Odd, R Harwood, J Ward, M Linney, M Clark, D Hargreaves, SN Ladhani, E Draper, PJ Davis, SE Kenny, E Whittaker, K Luyt, RM Viner, LK Fraser https://www.medrxiv.org/content/10.1101/2021.07.07.21259779v1

Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year, J L Ward, R Harwood, C Smith, S Kenny, M Clark, PJ Davis, ES Draper, D Hargreaves, S Ladhani, M Linney, K Luyt, S Turner, E Whittaker, L K Fraser, R.M Viner https://www.medrxiv.org/content/10.1101/2021.07.01.21259785v1

Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Peter J. Halfmann, Hannah E. Segaloff, Anna Kocharian, Kelsey R. Florek, Ryan Westergaard, Allen Bateman, Gunnar E. Jeppson, Yoshihiro Kawaoka, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v4

UK Government Recommendations on Vaccinating Children – Ages 12-15 https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-vaccination-of-children-aged-12-to-15

Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study, Semple et al. https://www.medrxiv.org/content/10.1101/2021.09.14.21263567v1

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum, Stuart P. Weisberg, Thomas J. Connors, Donna L. https://www.nature.com/articles/s41590-020-00826-9?campaign_id=154&emc=edit_cb_20201106&instance_id=23895&nl=coronavirus-briefing&regi_id=61609026&segment_id=43815&te=1&user_id=73aefc51739a420f3d188e5…

Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden, Jonas F. Ludvigsson, Lars Engerström, Charlotta Nordenhäll, Emma Larsson https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821981/

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA Vaccine, Ori Snapiri, Chen Rosenberg Danziger, Nina Shirman, Avichai Weissbach, Alexander Lowenthal, Itay Ayalon, Dganit Adam, Havatzelet Yarden-Bilavsky, Efraim Bilavsky https://pubmed.ncbi.nlm.nih.gov/34077949/

Myocarditis following COVID-19 mRNA vaccination, Saif Abu Mouch, Ariel Roguin, Elias Hellou, Amorina Ishai, Uri Shoshan, Lamis Mahamid, Marwan Zoabi, Marina Aisman, Nimrod Goldschmid, Noa Berar Yanay https://www.ncbi.nlm.nih.gov/pubmed/34535317

Myocarditis following COVID-19 vaccination, Albert, E., Aurigemma, G., Saucedo, J., Gerson, D. S. https://pubmed.ncbi.nlm.nih.gov/34092429/

Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination, Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. https://www.ncbi.nlm.nih.gov/pubmed/34586408

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting, Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. https://www.ncbi.nlm.nih.gov/pubmed/34432976

COVID19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis, Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., Bassareo, P. https://www.ncbi.nlm.nih.gov/pubmed/34564344

Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine, Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. https://www.ncbi.nlm.nih.gov/pubmed/34617315

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?, Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. https://www.ncbi.nlm.nih.gov/pubmed/34333695

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?, Das, B. B., Moskowitz, W. B., Taylor, M. B., Palmer, A. https://www.ncbi.nlm.nih.gov/pubmed/34356586

Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report, Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. https://www.ncbi.nlm.nih.gov/pubmed/34487236
Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination, Ioannou, A.https://www.ncbi.nlm.nih.gov/pubmed/34463755

Myocarditis Following COVID-19 Vaccination, Isaak, A., Feisst, A., & Luetkens, J. A. https://www.ncbi.nlm.nih.gov/pubmed/34342500

Myocarditis following COVID-19 vaccination, Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. https://www.ncbi.nlm.nih.gov/pubmed/34568540

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination, Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. https://www.ncbi.nlm.nih.gov/pubmed/34185046

Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination, Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. https://www.ncbi.nlm.nih.gov/pubmed/34402228

Why are we vaccinating children against COVID-19?, Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. https://www.ncbi.nlm.nih.gov/pubmed/34540594

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination, Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. https://www.ncbi.nlm.nih.gov/pubmed/33606296

Myocarditis following COVID-19 vaccination – A case series, Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. https://www.ncbi.nlm.nih.gov/pubmed/34535317

Vaccine advisory committee must be more transparent about decisions, Mahase, E. https://www.ncbi.nlm.nih.gov/pubmed/34620583

COVID vaccines cut the risk of transmitting Delta – but not for long, Mallapaty, S. https://www.ncbi.nlm.nih.gov/pubmed/34611341

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel, Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. https://www.ncbi.nlm.nih.gov/pubmed/34614328

COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India, Mishra, K., Barki, S., Pattanayak, S., Shyam, M., Sreen, A., Kumar, S., & Kotwal, J. https://www.ncbi.nlm.nih.gov/pubmed/34608364

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series, Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. https://www.ncbi.nlm.nih.gov/pubmed/34496880

A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products, Rose, J., & McCullough, P. A. https://www.ncbi.nlm.nih.gov/pubmed/34601006

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine, Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E., Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R.
Durable Natural Immunity https://www.ncbi.nlm.nih.gov/pubmed/34077949

One-year sustained cellular and humoral immunities of COVID-19 convalescents, Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab884/6381561#.YWGhCytQ_Hc.twitter https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab884/6381561#.YWGhCytQ_Hc.twitter

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections, Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon. https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1.full

Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar E. Jeppson, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v4

Necessity of COVID-19 vaccination in previously infected individuals, Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v2

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection, Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen. https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1.full

Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection, Ellie Ivanova, Joseph Devlin, et al. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3838993

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans, Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O’Halloran, Rachel M. Presti, Ali H. Ellebedy. https://www.nature.com/articles/s41586-021-03647-4

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et al. https://www.medrxiv.org/content/10.1101/2021.04.19.21255739v1
Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner https://www.medrxiv.org/content/10.1101/2021.07.03.21259976v2

Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine, Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi https://www.biorxiv.org/content/10.1101/2021.07.14.452381v1

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919858/

mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status, Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan. https://www.biorxiv.org/content/10.1101/2021.05.12.443888v2

Persistence of neutralizing antibodies a year after SARS-CoV-2 infection, Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin. https://www.medrxiv.org/content/10.1101/2021.07.13.21260426v1

Quantifying the risk of SARS‐CoV‐2 reinfection over time, Eamon O Murchu, Paula Byrne, Paul G. Carty, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209951/pdf/RMV-9999-e2260.pdf

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00141-3/fulltext#%20

Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati https://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1

Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al. https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1

Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al. https://pubmed.ncbi.nlm.nih.gov/33777028/

Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al. https://www.medrxiv.org/content/10.1101/2021.05.11.21256578v1

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, et al, Nature Communications. https://www.nature.com/articles/s41467-021-24377-1?utm_source=other&utm_medium=other&utm_content=null&utm_campaign=JRCN_1_LW01_CN_natureOA_article_paid_XMOL

Antibody Evolution after SARS-CoV-2 mRNA Vaccination, Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, et al. https://www.biorxiv.org/content/10.1101/2021.07.29.454333v1

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. et al. https://www.biorxiv.org/content/10.1101/2021.03.22.436441v1

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al. https://www.medrxiv.org/content/10.1101/2021.07.02.21259897v1

SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al. https://academic.oup.com/ofid/article/8/8/ofab378/6322055

Secondary household transmission of SARS-CoV-2 among children and adolescents: clinical and epidemiological aspects, Afonso, E. T., Marques, S. M., Costa, L. D. C., Fortes, P. M., Peixoto, F., Bichuetti-Silva, D. C., . . . Guimaraes, R. A. https://www.ncbi.nlm.nih.gov/pubmed/34590794

The role of children and adolescents in the transmission of SARS-CoV-2 virus within family clusters: A large population study from Oman, Alqayoudhi, A., Al Manji, A., Al Khalili, S., Al Maani, A., Alkindi, H., Alyaquobi, F., . . . Al-Abri, S. https://www.ncbi.nlm.nih.gov/pubmed/34627056

A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir, Leung, Y. H., Li, M. P., & Chuang, S. K. https://www.ncbi.nlm.nih.gov/pubmed/20561390

Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate, Madewell, Z. J., Yang, Y., Longini, I. M., Jr., Halloran, M. E., and Dean, N. E. https://www.ncbi.nlm.nih.gov/pubmed/32766596

Can children of the Sputnik V vaccine recipients become symptomatic?, Mehraeen, E., SeyedAlinaghi, S., and Karimi, A.
Effective Early Treatment https://www.ncbi.nlm.nih.gov/pubmed/34241575

A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, Abu Taiub Mohammed Mohiuddin Chowdhury, Mohammad Shahbaz, Md Rezaul Karim, Jahirul Islam, Guo Dan, Shuixiang He https://ejmo.org/pdf/A%20Comparative%20Study%20on%20IvermectinDoxycycline%20and%20HydroxychloroquineAzithromycin%20Therapy%20on%20COVID19%20Patients-16263.pdf

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study, Matthew S Freiberg, et al https://www.bmj.com/content/372/bmj.n311

Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, Reaz, Mahmud, Rahman, Mujibur, Iftikher, Alam, Ahmed, Kazi Gias Uddin, Kabir, A. K. M. Humayon, S. K. Jakaria Been, Mohammad Aftab, Mohammad Monirul, Anindita Das, Mohammad Mahfuzul, Mohammad Abdullah, Mohammad Zaid https://datadryad.org/stash/dataset/doi:10.5061/dryad.qjq2bvqf6

The Role of Steroids in the Management of COVID-19 InfectionZayar Lin, Wai Hnin Phyu, Zin Hnin Phyu, and Tin Zar Mon https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425064/

Antithrombotic Therapy to Ameliorate Complications of COVID-19, Brett L Houston et al https://pubmed.ncbi.nlm.nih.gov/32815416/

COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study, Roland Derwand, Martin Scholz, Vladimir Zelenko https://www.sciencedirect.com/science/article/pii/S0924857920304258?via%3Dihub

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19, Saiful Islam Kha, Sakirul Islam Khan, Chitto Ranjan Debnath, Progga Nanda Nath, Mamun Al Mahtab, Hiroaki Nabeka, Seiji Matsuda, Sheikh Mohammad Fazle Akbar https://www.sciencedirect.com/science/article/abs/pii/S030028962030288X?via%3Dihub#!

Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City, Jose Merino, Victor Hugo Borja, Oliva Lopez, José Alfredo Ochoa, Eduardo Clark, Lila Petersen, Saul Caballero https://osf.io/preprints/socarxiv/r93g4/

Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India, Ravikirti, Roy, R., Pattadar, C., Raj, R., Agarwal, N., Biswas, B., Manjhi, P. K., Rai, D. K., Shyama, Kumar, A., & Sarfaraz, A. https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32105

Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers, Simova T., Vekov J., Krasnaliev V., Kornovski P., Bozhinov https://www.sciencedirect.com/science/article/pii/S2052297520301657?via%3Dihub

Efficacy of a Low Dose of Melatonin… in Hospitalized Patients with COVID-19, GholamHossein Alishiri https://doi.org/10.1016/j.arcmed.2021.06.006

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19, Yaseen M. Arabi, George P. Chrousos & G. Umberto Meduri https://link.springer.com/article/10.1007/s00134-020-06223-y

Early short course corticosteroids in hospitalized patients with COVID-19 (Multi-center quasi-experimental study), Mayur S Ramesh et al. https://doi.org/10.1093/cid/ciaa601

Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I et al. https://www.medrxiv.org/content/10.1101/2020.05.18.20066902v1

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial, Lenze E et al. https://jamanetwork.com/journals/jama/fullarticle/2773108

Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, Di Pierro F et al. https://pubmed.ncbi.nlm.nih.gov/34135619/

Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study, Ooi ST et al. https://pubmed.ncbi.nlm.nih.gov/33235888/
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients, Carlucci P et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660893/
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, Kaufman H et al. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239252
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020, Taieb F et al. https://www.mdpi.com/2077-0383/10/13/2954
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I et al. https://www.medrxiv.org/content/10.1101/2020.05.18.20066902v1
Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety Evidence, Risch, Harvey. https://earlycovidcare.org/wp-content/uploads/2021/09/Evidence-Brief-Risch-v6.pdf
Metaanalyses and Aggregated Ivermectin Studies – 1 https://c19ivermectin.com/
Metaanalyses and Aggregated Hydroxychloroquin Studies – 1 https://hcqmeta.com/
Metaanalyses and Aggregated Ivermectin Studies – 1 https://ivmmeta.com/